Compare IMXI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMXI | LXEO |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 396.5M |
| IPO Year | 2016 | 2023 |
| Metric | IMXI | LXEO |
|---|---|---|
| Price | $11.35 | $4.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $15.00 | ★ $18.44 |
| AVG Volume (30 Days) | 385.0K | ★ 971.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $319,601,000.00 | $654,000.00 |
| Revenue This Year | $0.83 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $77.53 | ★ N/A |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $11.15 | $3.99 |
| 52 Week High | $15.95 | $10.99 |
| Indicator | IMXI | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 26.67 | 57.53 |
| Support Level | $11.15 | $4.39 |
| Resistance Level | $15.49 | $5.01 |
| Average True Range (ATR) | 0.54 | 0.30 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 11.06 | 84.79 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.